Leng X, Tang X, Hu P, Guan X, Li Q, Huang C
Front Immunol. 2023; 13:1110992.
PMID: 36926529
PMC: 10011485.
DOI: 10.3389/fimmu.2022.1110992.
Gao Q, Yin X, Tan B, Wang J, Chen J, Zhao B
BMC Infect Dis. 2022; 22(1):929.
PMID: 36503381
PMC: 9742033.
DOI: 10.1186/s12879-022-07896-0.
Zhang J, Zhang J, Zhang C, Zhang J, Gu L, Luo D
Cells. 2022; 11(21).
PMID: 36359761
PMC: 9655436.
DOI: 10.3390/cells11213362.
Terzi F, Demirci B, Cinar I, Alhilal M, Erol H
Respir Res. 2022; 23(1):249.
PMID: 36115998
PMC: 9482261.
DOI: 10.1186/s12931-022-02172-w.
Malek R, Bill C, Vines C
Biomed Pharmacother. 2021; 144:112276.
PMID: 34624681
PMC: 8486678.
DOI: 10.1016/j.biopha.2021.112276.
Interleukin-6 Trans-signaling: A Pathway With Therapeutic Potential for Diabetic Retinopathy.
Sharma S
Front Physiol. 2021; 12:689429.
PMID: 34093244
PMC: 8170152.
DOI: 10.3389/fphys.2021.689429.
Modeling and Simulation to Support Phase Ib/IIa Dose Selection for WBP216, A Long Half-Life Fully Human Monoclonal Antibody Against Interleukin-6.
Tang X, Zeng X, Guan X, Chen R, Hu P
Front Pharmacol. 2021; 12:617265.
PMID: 33679400
PMC: 7930490.
DOI: 10.3389/fphar.2021.617265.
The immunobiology of humanized Anti-IL6 receptor antibody: From basic research to breakthrough medicine.
Ohsugi Y
J Transl Autoimmun. 2020; 3:100030.
PMID: 32743515
PMC: 7388389.
DOI: 10.1016/j.jtauto.2019.100030.
Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis.
Mihara M, Ohsugi Y, Kishimoto T
Open Access Rheumatol. 2011; 3:19-29.
PMID: 27790001
PMC: 5074778.
DOI: 10.2147/OARRR.S17118.
Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study.
Nakamura S, Suzuki K, Iijima H, Hata Y, Lim C, Ishizawa Y
Arthritis Res Ther. 2016; 18:159.
PMID: 27435242
PMC: 4952232.
DOI: 10.1186/s13075-016-1052-8.
Circulating Levels of IL-6 Receptor and gp130 and Long-Term Clinical Outcomes in ST-Elevation Myocardial Infarction.
Ritschel V, Seljeflot I, Arnesen H, Halvorsen S, Eritsland J, Fagerland M
J Am Heart Assoc. 2016; 5(6).
PMID: 27412895
PMC: 4937252.
DOI: 10.1161/JAHA.115.003014.
Interrelationship Between Periapical Lesion and Systemic Metabolic Disorders.
Sasaki H, Hirai K, Martins C, Furusho H, Battaglino R, Hashimoto K
Curr Pharm Des. 2016; 22(15):2204-15.
PMID: 26881444
PMC: 4856634.
DOI: 10.2174/1381612822666160216145107.
Anti-proliferative action of IL-6R-targeted antibody tocilizumab for non-small cell lung cancer cells.
Kim N, Kim S, Kim D, Zhang D, Park J, Yi H
Oncol Lett. 2015; 9(5):2283-2288.
PMID: 26137057
PMC: 4467318.
DOI: 10.3892/ol.2015.3019.
Interrelated reduction of chemerin and plasminogen activator inhibitor-1 serum levels in rheumatoid arthritis after interleukin-6 receptor blockade.
Makrilakis K, Fragiadaki K, Smith J, Sfikakis P, Kitas G
Clin Rheumatol. 2014; 34(3):419-27.
PMID: 24912961
DOI: 10.1007/s10067-014-2704-1.
SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model.
Kim G, Ouzounova M, Quraishi A, Davis A, Tawakkol N, Clouthier S
Oncogene. 2014; 34(6):671-80.
PMID: 24531711
PMC: 4285772.
DOI: 10.1038/onc.2014.4.
New era of biologic therapeutics in atopic dermatitis.
Guttman-Yassky E, Dhingra N, Leung D
Expert Opin Biol Ther. 2013; 13(4):549-61.
PMID: 23323893
PMC: 3819721.
DOI: 10.1517/14712598.2013.758708.
Regulation of cancer stem cells by cytokine networks: attacking cancer's inflammatory roots.
Korkaya H, Liu S, Wicha M
Clin Cancer Res. 2011; 17(19):6125-9.
PMID: 21685479
PMC: 3312242.
DOI: 10.1158/1078-0432.CCR-10-2743.
Anti-IL-6 receptor antibody causes less promotion of tuberculosis infection than anti-TNF-α antibody in mice.
Okada M, Kita Y, Kanamaru N, Hashimoto S, Uchiyama Y, Mihara M
Clin Dev Immunol. 2011; 2011:404929.
PMID: 21603208
PMC: 3095415.
DOI: 10.1155/2011/404929.
Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).
Ghoreschi K, Jesson M, Li X, Lee J, Ghosh S, Alsup J
J Immunol. 2011; 186(7):4234-43.
PMID: 21383241
PMC: 3108067.
DOI: 10.4049/jimmunol.1003668.
Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization.
Igawa T, Ishii S, Tachibana T, Maeda A, Higuchi Y, Shimaoka S
Nat Biotechnol. 2010; 28(11):1203-7.
PMID: 20953198
DOI: 10.1038/nbt.1691.